ASCO 2022 | E3311: exploring deintensification of adjuvant treatment in patients with intermediate risk HPV+ OPC

Ranee Mehra, MD, University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore, MD, provides an overview of the randomized Phase II E3311 (NCT01898494) study investigating patients with intermediate risk HPV+ oropharynx cancer (OPC) who underwent transoral surgery (TOS) followed by pathology-guided or adapted, deintensified adjuvant treatment. Patients who were classified as low-risk received no further treatment, those who were identified as high-risk received cisplatin with a radiation at a dose of 66 Gy as adjuvant treatment. Patients who were identified as intermediate-risk were randomized to receive either 50 Gy or 60 Gy of radiation to determine whether deintensification of adjuvant treatment is feasible for this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.